The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure
The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure
复制标题
DOI：
10.1016/s0002-9343(98)00111-9
复制
发表时间：
1998-06-01
影响因子：
5.9
通讯作者：
Kramer, WG
中科院分区：
文献类型：
--
作者：
Gottlieb, SS;Khatta, M;Kramer, WG
目得：为了评估利尿前后的呋塞米和托拉塞米的药代动力学患者提出了显着的液体overload. Subjections和方法：我们研究了44例纽约心脏协会III级或IV级心力衰竭，射血分数小于或等于40%，估计多余的液体体重大于或等于6.8公斤。利尿前后口服呋塞米或托拉塞米。结果：利尿后，托拉塞米的最大血药浓度从11.0 +/- 5.0 μ g/mL增加到13.9 +/- 6.8 μ g/mL（P <30%，仅1例托拉塞米和2例呋塞米患者。托拉塞米组达峰时间从1.40 ± 0.82 h降至0.81 ± 0.36 h（P
PURPOSE: To evaluate the pharmacokinetics of furosemide and torsemide before and after diuresis in patients presenting with marked fluid overload.SUBJECTS AND METHODS: We studied 44 patients with New York Heart Association class III or IV heart failure, ejection fraction less than or equal to 40%, and an estimated excess fluid body weight greater than or equal to 6.8 kg. Oral furosemide or torsemide was administered before and after diuresis. Pharmacokinetic parameters were assessed before and after diuresis.RESULTS: Following diuresis, maximum plasma concentration increased from 11.0 +/- 5.0 mu g/mL to 13.9 +/- 6.8 with torsemide (P 30% in only 1 torsemide and 2 furosemide patients. The time to maximum concentration decreased from 1.40 +/- .82 h to 0.81 +/- 0.36 with torsemide (P